🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against drug-resistant strains of the infection, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are escalating worldwide, with data suggesting over 82 million infections each year. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices at this time.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists believe that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Testing Results and Global Access

As per results published in a prominent scientific publication, zoliflodacin cured over nine in ten of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which combines a dual-drug approach. The study involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to register and commercialise the drug in many developing nations.

Clinicians on the front lines have voiced optimism. The availability of a one-pill regimen of this kind is seen as a "critical tool" for gonorrhoea control. This is viewed as crucial to reduce the burden of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.